Quoin Pharmaceuticals Ltd.

Snapshot

Quoin is a pre-revenue biotech developing rare-disease skin treatments, with $0 in sales and a $15.8M net loss in FY 2025.

What's Happening Right Now

• Fri 28th Aug '26 · Trial data: On Aug 28, 2026, Quoin reported positive interim Phase 2/3 data for QRX003 in Netherton Syndrome, with 4 of 6 patients hitting the primary endpoint at statistical significance and no treatment-related serious side effects.
• Fri 28th Aug '26 · Financing: On Aug 28, 2026, Quoin priced a private placement of up to $50M (about $30.8M upfront), which it says extends its cash runway into the second half of 2029.
• Fri 14th Aug '26 · Regulatory: On Aug 14, 2026, Quoin disclosed FDA conditional approval of the brand name QYLEKI for QRX003, a new patent allowance for a Netherton Syndrome combination treatment, and clearance to start a Phase 2/3 study in Peeling Skin Syndrome.
• Thu 9th Jul '26 · Regulatory: On Jul 9, 2026, the FDA cleared Quoin's IND to begin a Phase 2 study of QRX003 in Peeling Skin Syndrome, expected to start in the second half of 2026.
• Thu 18th Jun '26 · Expansion: On Jun 18, 2026, Quoin completed a Japanese subsidiary to support planned direct commercialization of QRX003 there, following Japan's orphan drug designation for the product.